[go: up one dir, main page]

CL2014001309A1 - Compuestos derivados de [1,2,3] triazolo [4,5-d]-pirimidina, agonistas del receptor de canabinoides 2; proceso de obtencion; composicion farmaceutica; uso para el tratamiento o la profilaxis del dolor, aterosclerosis,retinopatia diabetica, diabetes, fibrosis hepatica, fallo cardiaco, entre otras. - Google Patents

Compuestos derivados de [1,2,3] triazolo [4,5-d]-pirimidina, agonistas del receptor de canabinoides 2; proceso de obtencion; composicion farmaceutica; uso para el tratamiento o la profilaxis del dolor, aterosclerosis,retinopatia diabetica, diabetes, fibrosis hepatica, fallo cardiaco, entre otras.

Info

Publication number
CL2014001309A1
CL2014001309A1 CL2014001309A CL2014001309A CL2014001309A1 CL 2014001309 A1 CL2014001309 A1 CL 2014001309A1 CL 2014001309 A CL2014001309 A CL 2014001309A CL 2014001309 A CL2014001309 A CL 2014001309A CL 2014001309 A1 CL2014001309 A1 CL 2014001309A1
Authority
CL
Chile
Prior art keywords
triazolo
prophylaxis
atherosclerosis
pyrimidine
diabetes
Prior art date
Application number
CL2014001309A
Other languages
English (en)
Inventor
Uwe Grether
Atsushi Kimbara
Matthias Nettekoven
Stephan Roever
Amrk Rogers-Evans
Caterina Bissantz
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2014001309A1 publication Critical patent/CL2014001309A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
CL2014001309A 2011-11-25 2014-05-19 Compuestos derivados de [1,2,3] triazolo [4,5-d]-pirimidina, agonistas del receptor de canabinoides 2; proceso de obtencion; composicion farmaceutica; uso para el tratamiento o la profilaxis del dolor, aterosclerosis,retinopatia diabetica, diabetes, fibrosis hepatica, fallo cardiaco, entre otras. CL2014001309A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11190777 2011-11-25

Publications (1)

Publication Number Publication Date
CL2014001309A1 true CL2014001309A1 (es) 2014-10-17

Family

ID=47278275

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014001309A CL2014001309A1 (es) 2011-11-25 2014-05-19 Compuestos derivados de [1,2,3] triazolo [4,5-d]-pirimidina, agonistas del receptor de canabinoides 2; proceso de obtencion; composicion farmaceutica; uso para el tratamiento o la profilaxis del dolor, aterosclerosis,retinopatia diabetica, diabetes, fibrosis hepatica, fallo cardiaco, entre otras.

Country Status (32)

Country Link
US (1) US9067943B2 (es)
EP (1) EP2782915B1 (es)
JP (1) JP6077558B2 (es)
KR (1) KR20140097201A (es)
CN (1) CN104039791B (es)
AR (1) AR088970A1 (es)
AU (1) AU2012342471B2 (es)
BR (1) BR112014012479A2 (es)
CA (1) CA2850697A1 (es)
CL (1) CL2014001309A1 (es)
CO (1) CO6930360A2 (es)
CR (1) CR20140222A (es)
CY (1) CY1116984T1 (es)
DK (1) DK2782915T3 (es)
EA (1) EA024108B1 (es)
ES (1) ES2550967T3 (es)
HR (1) HRP20151423T1 (es)
HU (1) HUE028020T2 (es)
IL (1) IL232304A (es)
MA (1) MA35663B1 (es)
MX (1) MX346248B (es)
PE (1) PE20141578A1 (es)
PH (1) PH12014501026A1 (es)
PL (1) PL2782915T3 (es)
PT (1) PT2782915E (es)
RS (1) RS54319B1 (es)
SG (1) SG11201402198XA (es)
SI (1) SI2782915T1 (es)
TW (1) TWI598350B (es)
UA (1) UA111643C2 (es)
WO (1) WO2013076182A1 (es)
ZA (1) ZA201403441B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA111640C2 (uk) * 2011-11-08 2016-05-25 Ф. Хоффманн-Ля Рош Аг ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2
MY191628A (en) * 2013-09-06 2022-07-04 Hoffmann La Roche Novel triazolo[4,5-d]pyrimidine derivatives
BR112017009629A2 (pt) 2014-11-07 2017-12-19 Hoffmann La Roche triazolo [4,5-d] pirimidinas como agonistas do receptor canabinoide 2
WO2017004133A1 (en) * 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
EP3475283B1 (en) * 2016-06-23 2021-08-11 F. Hoffmann-La Roche AG Novel[1,2,3]triazolo[4,5-d]pyrimidine derivatives
SG11201809678VA (en) * 2016-06-23 2018-11-29 Hoffmann La Roche [1,2,3]triazolo[4,5-d]pyrimidine derivatives with affinity for the type-2 cannabinoid receptor
WO2018015088A1 (en) 2016-06-23 2018-01-25 F. Hoffmann-La Roche Ag Novel [1,2,31triazolo[4,5-d]pyrimidine derivatives
WO2017220516A1 (en) * 2016-06-23 2017-12-28 F. Hoffmann-La Roche Ag Novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives
CA3099080A1 (en) * 2018-05-04 2019-11-07 Inflazome Limited Novel compounds
CN112007156A (zh) * 2019-05-30 2020-12-01 复旦大学 大麻素受体药物在制备治疗心肌细胞坏死性凋亡药剂中的应用
CN112755189A (zh) * 2019-11-02 2021-05-07 复旦大学 1型大麻素受体拮抗剂在制备治疗心肌细胞焦亡药剂中的应用
WO2023072978A1 (en) * 2021-10-28 2023-05-04 F. Hoffmann-La Roche Ag Synthesis of [1,2,3]triazolo[4,5-d]pyrimidines
CN115246832B (zh) * 2022-06-15 2024-05-24 深圳湾实验室 一类去泛素化酶usp25和usp28靶向抑制剂及制备和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2543333A (en) * 1950-02-02 1951-02-27 American Cyanamid Co Derivatives of upsilon-triazolo (d) pyrimidine and methods of preparing the same
US4157443A (en) * 1976-11-11 1979-06-05 Ciba-Geigy Corporation V-Triazolyl-[4,5-d]-pyrimidines
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
WO2005061505A1 (en) 2003-12-16 2005-07-07 Pfizer Products Inc. Bicyclic imidazolyl pyrimidin-4-one cannabinoid receptor ligands and uses thereof
DE102004014534A1 (de) * 2004-03-23 2005-10-13 Basf Ag Triazolderivate und Verwendung von Triazolderivaten in organischen Leuchtdioden (OLEDs)
AR051596A1 (es) * 2004-10-26 2007-01-24 Irm Llc Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios
WO2008032764A1 (en) * 2006-09-13 2008-03-20 Kyowa Hakko Kirin Co., Ltd. Fused heterocyclic derivative
WO2009012573A1 (en) * 2007-07-20 2009-01-29 Merck Frosst Canada Ltd. Bicyclic heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
US7655685B2 (en) 2007-11-02 2010-02-02 Jenrin Discovery, Inc. Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
UA104010C2 (en) * 2008-12-18 2013-12-25 Эли Лилли Энд Компани Purine compounds
AR080711A1 (es) * 2010-03-31 2012-05-02 Lilly Co Eli Compuesto de piperazin-purina composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento o prevencion del dolor
ES2481867T3 (es) 2010-03-31 2014-07-31 Eli Lilly And Company Compuestos de purina usados como agonistas de CB2
UA111640C2 (uk) * 2011-11-08 2016-05-25 Ф. Хоффманн-Ля Рош Аг ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2

Also Published As

Publication number Publication date
AU2012342471A1 (en) 2014-04-10
DK2782915T3 (en) 2015-10-19
SI2782915T1 (sl) 2015-12-31
CA2850697A1 (en) 2013-05-30
PT2782915E (pt) 2015-11-19
IL232304A (en) 2016-02-29
ZA201403441B (en) 2015-08-26
MA35663B1 (fr) 2014-11-01
PE20141578A1 (es) 2014-10-25
EP2782915B1 (en) 2015-09-30
PH12014501026A1 (en) 2014-06-23
TWI598350B (zh) 2017-09-11
US9067943B2 (en) 2015-06-30
CY1116984T1 (el) 2017-04-05
JP2014533711A (ja) 2014-12-15
HRP20151423T1 (hr) 2016-01-29
KR20140097201A (ko) 2014-08-06
CO6930360A2 (es) 2014-04-28
MX346248B (es) 2017-03-13
CN104039791B (zh) 2016-11-09
SG11201402198XA (en) 2014-09-26
EA024108B1 (ru) 2016-08-31
AU2012342471B2 (en) 2017-06-08
CN104039791A (zh) 2014-09-10
UA111643C2 (uk) 2016-05-25
RS54319B1 (sr) 2016-02-29
AR088970A1 (es) 2014-07-23
HUE028020T2 (en) 2016-11-28
CR20140222A (es) 2014-06-20
TW201329080A (zh) 2013-07-16
EP2782915A1 (en) 2014-10-01
NZ622847A (en) 2015-05-29
EA201491002A1 (ru) 2014-09-30
BR112014012479A2 (pt) 2017-06-06
JP6077558B2 (ja) 2017-02-08
WO2013076182A1 (en) 2013-05-30
PL2782915T3 (pl) 2016-03-31
US20130137676A1 (en) 2013-05-30
ES2550967T3 (es) 2015-11-13
MX2014005692A (es) 2014-07-28
IL232304A0 (en) 2014-06-30

Similar Documents

Publication Publication Date Title
CL2014001309A1 (es) Compuestos derivados de [1,2,3] triazolo [4,5-d]-pirimidina, agonistas del receptor de canabinoides 2; proceso de obtencion; composicion farmaceutica; uso para el tratamiento o la profilaxis del dolor, aterosclerosis,retinopatia diabetica, diabetes, fibrosis hepatica, fallo cardiaco, entre otras.
CL2014001174A1 (es) Compuestos derivados de [1,2,3]triazolo[4,5-d]pirimidina y sus sales, como agonistas del receptor de canabinoides 2; su proceso de obtencion; composicion farmaceutica que los contiene; y su uso para el tratamiento o profilaxis del dolor, aterosclerosis, inflamacion, glaucoma, ataque isquemico transitorio, entre otras enfermedades.
CL2015001538A1 (es) Compuestos derivados de piridin-2-amidas, agonistas cb2; proceso de preparacion; composicion farmaceutica que los contiene; su uso para el tratamiento o profilaxis del dolor, aterosclerosis, retinopatia diabetica, glaucoma, diabetes mellitus, entre otras.
UY35040A (es) Pirrolopirimidinilamino-benzotiazolonas sustituidas
CL2013002053A1 (es) Compuestos derivados de heterociclicos, antagonistas del receptor de glucagon; composicion farmaceutica que lo comprende y su uso en el tratamiento de diabetes y enfermedades metabolicas. pct
CL2013003262A1 (es) Compuestos derivados de 1,3-oxazinas, con actividad inhibidora de bace 1 y/o bace2; composición farmacéutica que los comprende; procedimiento de preparación; uso en el tratamiento de la enfermedad de alzheimer, diabetes, trombosis arterial, cáncer, infarto al miocardio, entre otras patologías.
CL2012003604A1 (es) Compuestos heterociclicos derivados de piridina carboxamida sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos proliferativos celulares, enfermedad de parkinson, cancer, entre otros.
CL2015001537A1 (es) Compuestos derivados de piridin-2-amidas agonistas cb2; proceso de sintesis; composicion farmaceutica; uso en el tratamiento o profilaxis del dolor, aterosclerosis, retinopatia diabetica, glaucoma, diabetes mellitus, entre otras.
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
CL2015001536A1 (es) Compuestos derivados de piridina, agonistas del receptor de canabinoides 2; proceso de sintesis; su uso para el tratamiento o profilaxis del dolor, aterosclerosis, retinopatia diabetica, infarto de miocardio, apoplejia, entre otras.
CL2015002635A1 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CL2013002414A1 (es) Compuestos derivados de azabencimidazol ciclico, activadores de la proteina cinasa activada por amp; composicion farmaceutica que los comprende; y su uso para el tratamiento o enfermedad tal como diabetes tipo 2, hiperglicemia, sindrome metabolico, obesidad, hipercolesterolemia e hipertension.
CL2014002983A1 (es) Compuestos derivados de 1h-pirazolo[3,4-b]piridina, como inhibidores de una o mas proteinas en la ruta de wnt; composicion farmaceutica que los comprende, util para el tratamiento de cancer, retinopatia diabetica, fibrosis pulmonar, artritis reumatoide, enfermedad de alzheimer, entre otras.
CL2008000875A1 (es) Compuestos derivados de imidazolidin-2-ona; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento y/o profilaxis de enfermedades tales como dislipidemia, diabetes, enfermedades inflamatorias, entre otras.
CL2014002412A1 (es) Compuestos derivados de pirido[4,3-d]pirimidina, como inhibidores de mek; composicion farmaceutica que los comprende; y su uso para el tratamiento de enfermedades inflamatorias, infecciones, trastornos autoinmunes, enfermedades metabolicas y enfermedades malignas, entre otras.
CL2015001318A1 (es) Compuestos derivados de pirazina, agonistas del receptor cb2; proceso de obtencion; composicion farmaceutica y el uso en el tratamiento de enfermedades tales como aterosclerosis, glaucoma, diabetes, entre otras.
CL2013003598A1 (es) Compuestos derivados de benzooxazepinona, moduladores de canales de sodio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades seleccionadas de arritmias, insuficiencia cardiaca, angina, infarto al miocardio, diabetes, entre otras
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
CL2016001895A1 (es) Compuestos
CL2013003051A1 (es) Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio
CL2013000714A1 (es) Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso de preparacion; composicion farmaceutica que los comprende; metodo de tratamiento; y uso del compuesto para tratar enfermedades tales como diabetes tipo 2, sindrome metabolico, dislipidemia, hipertension y esquizofrenia, entre otras.
GT201400111A (es) Triazolopiridinas sustituidas
CL2007002121A1 (es) Compuestos derivados de pirazoles, activadores de glucoquinasa; proceso de preparacion de dichos compuestos; composicion farmaceutica que comprende dichos compuestos; y uso para el tratamiento de enfermedades y/o trastornos metabolicos, tal como diab
CL2008000806A1 (es) Compuestos derivados de aza piridopirimidinona, con actividad agonista de hm74a; procedimiento de preparacion de dichos compuestos; composicion farmaceutico que las comprende; y su uso para preparar medicamentos para el tratamiento de enferemedades ateroscleroticas, dislipidemias, alzheimer, diabetes, entre otras.
CL2008000905A1 (es) Compuestos derivados de morfina, antagonistas del receptor opioide periferico; metodo de preparacion; composicion farmaceutica; y uso para reducir los efectos de la actividad opioide endogena.